Domestic pharmaceutical firms urged to nurture non-flagship products

Published: 2004-05-17 07:00:00

Updated: 2004-05-17 07:00:00

Major domestic pharmaceutical firms have relied heavily on flagship products to achieve their sales target amid protracted business slump, but market analysts say that there is an urgent need to cultivate non-flagship products to cushion the lackluster sales of these products that might affect th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK